September 2026 saw continued dealmaking across the antibody biotechnology sector, with major licensing agreements, strategic collaborations, mergers, and financing rounds. Multispecific antibodies and T-cell engagers attracted substantial pharmaceutical investment, while antibody-drug conjugates (ADCs) remained an active area of oncology development. AI-driven protein design, autoimmune disease therapies, and next-generation antibody platforms also drew new financing and research partnerships.
Multispecific antibodies and T-cell engagers attracted major licensing deals
ADCs and antibody-based oncology therapies remained a focus of investment
Next-generation antibody platforms and AI-driven drug discovery continued to attract funding
Aethlon Medical × North Immunology – Aethlon Medical and North Immunology announced a merger alongside a $180M private placement. The transaction is focused on advancing a novel IL-13 x IL-18 bispecific antibody for atopic dermatitis, targeting inflammatory pathways associated with the disease.
Lisata Therapeutics × Marea Therapeutics – Lisata Therapeutics announced the acquisition of Marea Therapeutics and a concurrent $225M private placement. The transaction is intended to support development of the combined company's antibody pipeline.
Simcere Zaiming × Roche – Simcere Zaiming entered a $1.53B global licensing agreement with Roche for SIM0660, a trispecific antibody targeting B-cell-mediated diseases. Roche will lead global development of the program, which is designed to address immune-mediated disease through multispecific antibody targeting.
HUTCHMED × GSK – HUTCHMED announced a $1.3B licensing agreement with GSK for HMPL-A830, a KRAS-EGFR antibody-targeted-therapy-conjugate (ATTC) being developed for cancer treatment. The program represents an approach to antibody-based targeted therapy combining molecular targeting with conjugate technology.
GSK × Chimagen Biosciences – GSK agreed to acquire full global rights to Chimagen's trispecific T-cell engager for multiple myeloma in a deal worth up to $750M. The program uses a multispecific antibody approach to engage T cells against malignant cells.
Dualitas Therapeutics × Roche – Dualitas Therapeutics announced a potential $1B proximity biology research collaboration with Roche to discover and develop novel bispecific antibodies for inflammatory and immunological (I&I) diseases. The collaboration will apply Dualitas' proximity biology approach to therapeutic antibody discovery.
Amberstone Biosciences × Henlius – Amberstone Biosciences and Henlius entered a $440M collaboration and license agreement to develop conditionally activated T-cell engagers for solid tumors. The collaboration focuses on next-generation immunotherapies designed to activate T-cell engagement under specific biological conditions.
Earendil Labs × Genentech – Earendil Labs announced a $1.5B+ research collaboration with Genentech to discover and develop therapeutic bispecific antibodies in oncology. The agreement supports the development of novel antibody candidates through collaborative research and discovery activities.
Tolerance Bio × Tanabe Pharma – Tolerance Bio licensed a clinical-stage anti-IL-33 monoclonal antibody from Tanabe Pharma in a potential $560M agreement. The transaction expands Tolerance Bio's thymus-focused clinical pipeline and adds an antibody targeting the IL-33 inflammatory signaling pathway.
Styx Biotechnologies × ZoeNCure Therapeutics – Styx Biotechnologies announced a strategic agreement with ZoeNCure Therapeutics to accelerate a next-generation ADC pipeline toward clinical development. The collaboration focuses on advancing antibody-based conjugate candidates through preclinical development.
AstraZeneca × Summit Therapeutics – AstraZeneca announced a $2B investment and clinical collaboration with Summit Therapeutics to advance sonesitatug vedotin, a Claudin-18.2-targeting ADC, in combination with ivonescimab for cancer treatment. The collaboration will evaluate a combination of antibody-based therapeutic approaches in oncology.
Cloverleaf Bio – Raised $33M in seed financing to advance novel cancer therapeutics, including an antibody-tRNA conjugate (ATC) asset targeting colorectal cancer. The program combines antibody-based targeting with RNA-related therapeutic technology.
Pyxis Oncology – Announced the pricing of a public offering of up to $282.6M. The financing will support advancement of its lead ADC candidate and associated development activities.
BigHat Biosciences – Raised $75M Series C financing to advance AI-designed therapeutics and its agentic data platform for rapid protein design. The investment supports the company's approach to integrating computational protein engineering with experimental drug discovery.
Solstice Oncology – Launched with $225M Series A financing to advance porustobart, an Fc-enhanced CTLA-4 antibody, as a neoadjuvant immuno-oncology therapy. The program focuses on using antibody-mediated immune modulation in cancer treatment.
Yarrow Bioscience – Closed a $172.5M underwritten public offering. The company is developing YB-101, an anti-thyroid stimulating hormone receptor monoclonal antibody designed to disrupt the central disease mechanism of both Graves' disease and thyroid eye disease.
NovaGo Therapeutics – Announced the completion of $30M Series B financing to advance a proof-of-concept study in acute spinal cord injury using a fully human therapeutic antibody. The financing was completed in August 2026 and announced in September.
Shennon Biotechnologies – Raised $12M in financing to develop antibody-based T-cell engagers (Ab-TCEs) and TCR-based T-cell engagers (TCR-TCEs). The investment supports its precision immunotherapy pipeline.
Electra Therapeutics – Announced the pricing of an upsized $350M initial public offering. The proceeds will help advance its lead monoclonal antibody asset, ipsoprubart.
ai3Bio – Launched with $48M Series A financing to advance proprietary antibody and lipid nanoparticle-based technologies for autoimmune disease. Its platform focuses on developing therapeutic approaches intended to address underlying mechanisms of immune dysfunction.
September 2026 antibody biotech dealmaking highlighted continued interest in multispecific antibody formats, T-cell engagers, and ADCs. Major licensing agreements involving Roche, GSK, and Genentech reflected pharmaceutical investment in next-generation antibody therapeutics across oncology and immune-mediated diseases.
Financing activity also supported a diverse range of antibody programs, from Fc-engineered immunotherapies and clinical-stage monoclonal antibodies to AI-enabled protein design and antibody conjugate technologies. Together, these transactions reflect the expanding role of antibody engineering, targeted therapeutic delivery, and computational discovery in the development of new biologics.
Recombinant antibody production involves introducing the genetic sequence encodi……
Antibody discovery has traditionally relied on screening large libraries of mole……
As AI models become more involved in antibody discovery and design, the need for……
You can also contact us on the Scientist and Science Exchange marketplaces.